The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
Objective: To determine the relationship of baseline quantitative BCR ABL1 gene percentage and therapeutic response i.e. Early Molecular Response (EMR) at 3 months with first generation Tyrosine kinase inhibitors (Imatinib) in patients with Chronic Myeloid Leukemia (CML) in chronic phase (CP). St...
Saved in:
Main Authors: | Amjad Khan, Riaz Ahmed, Sarah Fatimah, Muhammad Nadeem, Shama Iqbal, Sayed Tanveer Abbas Gilani, Huma Amjad |
---|---|
Format: | article |
Language: | EN |
Published: |
Army Medical College Rawalpindi
2021
|
Subjects: | |
Online Access: | https://doi.org/10.51253/pafmj.v71iSuppl-1.3891 https://doaj.org/article/846cf15589294effabd70c5c81935f9c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1
by: Yao-hua Lu, et al.
Published: (2021) -
Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors
by: Yi-Hue Kuo, et al.
Published: (2021) -
EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
by: Abdul Ali Wajid, et al.
Published: (2018) -
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
by: Haidée Aranda-Tavío, et al.
Published: (2021) -
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
by: Wang T, et al.
Published: (2019)